Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ºñÈ£ÁöŲ¸²ÇÁÁ¾¿¡¼­ ¾ÆÆ÷ÇÁÅä½Ã½º ¹× ¼¼Æ÷Áõ½Ä : Bcl-2, P53 ´Ü¹é¹ßÇö°úÀÇ °ü°è Apoptosis and Proliferative Activity of Non-Hodgkin's Lymphoma : Correlation with Bcl-2 and P53 Protein Expression

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2002³â 20±Ç 1È£ p.73 ~ 80
¼Ò¼Ó »ó¼¼Á¤º¸
¿ÀÀ±°æ/Yoon Kyeong Oh À̹ÌÀÚ/ÀüÈ£Á¾/Mi Ja Lee/Ho Jong Jeon

Abstract

¸ñÀû: Á¾¾çÀÇ ¼ºÀåÀº ¼¼Æ÷ÀÇ Áõ½Ä°ú ¼Ò½ÇÀÇ ¼ø¼öÇÑ °á°úÀ̸ç, ´ëºÎºÐÀÇ Á¾¾çµé¿¡¼­ ¾ÆÆ÷ÇÁÅä½Ã½º´Â °è¼ÓµÇ´Â ¼¼Æ÷ ¼Ò½ÇÀÇ °¡Àå Áß¿äÇÑ ºÎºÐÀ» Â÷ÁöÇÏ°í ÀÖ´Ù. º» ¿¬±¸¿¡¼­´Â ºñÈ£ÁöŲ¸²ÇÁÁ¾ ȯÀÚµéÀ» REAL ºÐ·ù¿¡ µû¶ó ÀçºÐ·ùÇÑ ´ÙÀ½ ¸é¿ªÁ¶Á÷È­ÇÐ ¿°»öÀ»
ÀÌ¿ëÇÏ¿©
¾ÆÆ÷ÇÁÅä½Ã½º Áö¼ö, Ki-67 ¼¼Æ÷Áõ½ÄÁö¼ö, Bcl-2 ´Ü¹é ¹ßÇö, P53 ´Ü¹é ¹ßÇöÀ» °üÂûÇÏ¿© Á¾¾çÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ÁÖ´Â ¿©·¯ ÀÎÀÚµéÀÇ °ü·Ã ¾ç»óÀ» ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù. ´ë»ó ¹× ¹æ¹ý: ºñÈ£ÁöŲ¸²ÇÁÁ¾ ȯÀÚ 67¸íÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. Working FormulationÀ»
ÀÌ¿ëÇÏ¿©
ºÐ·ùÇÏ¿´À» ¶§ Àúµî±ÞÀÌ 3¸í, Áßµî±ÞÀÌ 64¸íÀ̾ú´Ù. ¼¼Æ÷ Ç¥ÇöÇüÀº Àüü 67¸íÀÇ È¯ÀÚ Áß 47¸í(70%)ÀÌ B¼¼Æ÷ Ç¥ÇöÇüÀ̾ú°í, 18¸í(27%)ÀÌ T¼¼Æ÷ Ç¥ÇöÇüÀ̾úÀ¸¸ç, 2¸í¿¡¼­´Â ºÐ·ùÇÒ ¼ö ¾ø¾ú´Ù. ȯÀÚÀÇ ÆĶóÇÉ Æ÷¸Å Á¶Á÷À» ÀÌ¿ëÇÏ¿© ¸é¿ªÁ¶Á÷È­ÇÐ ¿°»öÀ» ½Ç½ÃÇÏ¿©
¾ÆÆ÷ÇÁÅä½Ã½º
Áö¼ö¿Í Ki-67 ¼¼Æ÷Áõ½ÄÁö¼ö, Bcl-2 ´Ü¹é¹ßÇö, P53 ´Ü¹é¹ßÇöÀ» °üÂûÇÏ¿´´Ù. °á°ú: Bcl-2 ´Ü¹éÀÇ ¹ßÇöÀº 40% (26/65)¿¡¼­ ¾ç¼º ¹ÝÀÀÀ» º¸¿´´Ù. P53 ´Ü¹éÀÇ ¹ßÇöÀº 31% (20/65)¿¡¼­ º¸¿´´Ù. ¾ÆÆ÷ÇÁÅä½Ã½º Áö¼ö´Â 0%¿Í 15%»çÀÌÀÇ ¹üÀ§¿¡ ÀÖ¾úÀ¸¸ç Æò±ÕÀº
2.16ÀÌ°í
Áß¾Ó°ªÀº 1.2À̾ú´Ù. ¾ÆÆ÷ÇÁÅä½Ã½º Áö¼ö´Â ¼¼Æ÷ Ç¥ÇöÇüÀ̳ª P53 ´Ü¹é¹ßÇö ¿©ºÎ¿¡ µû¶ó ÀÇ¹Ì ÀÖ´Â Â÷À̸¦ º¸ÀÌÁö ¾Ê¾ÒÀ¸³ª, Bcl-2 ´Ü¹é¹ßÇö ¿©ºÎ¿¡ µû¶ó¼­´Â Åë°èÇÐÀûÀ¸·Î ÀÇ¹Ì ÀÖ´Â Â÷À̸¦ º¸¿´´Ù(p=0.005). Bcl-2 ´Ü¹é¹ßÇöÀÌ ¾ç¼ºÀÌ¸é ¾ÆÆ÷ÇÁÅä½Ã½º Áö¼ö°¡ ³·¾Ò´Ù.
Ki-67
¼¼Æ÷Áõ½ÄÁö¼ö´Â 1%¿Í 91% »çÀÌÀÇ ¹üÀ§¿¡ ÀÖ¾úÀ¸¸ç Æò±ÕÀº 55.4%À̾ú´Ù. Ki-67 ¼¼Æ÷Áõ½ÄÁö¼ö´Â ¼¼Æ÷Ç¥ÇöÇüÀ̳ª Bcl-2 ´Ü¹é¹ßÇö ¿©ºÎ¿¡ µû¶ó ÀÇ¹Ì ÀÖ´Â Â÷À̸¦ º¸ÀÌÁö ¾Ê¾ÒÀ¸³ª, P53 ´Ü¹é¹ßÇö ¿©ºÎ¿¡ µû¶ó¼­´Â Åë°èÇÐÀûÀ¸·Î ÀÇ¹Ì ÀÖ´Â Â÷À̸¦ º¸¿´´Ù(p=0.000). Àüü
ȯÀÚ±º¿¡¼­´Â ¾ÆÆ÷ÇÁÅä½Ã½º Áö¼ö¿Í Ki-67 ¼¼Æ÷Áõ½ÄÁö¼ö »çÀÌ¿¡ °ü·ÃÀÌ ¾ø¾úÀ¸³ª, Bcl-2 ´Ü¹é¹ßÇö ¾ç¼ºÀΠȯÀÚ¿¡¼­´Â ¾ÆÆ÷ÇÁÅä½Ã½º Áö¼ö°¡ Áõ°¡Çϸé Ki-67 ¼¼Æ÷Áõ½ÄÁö¼ö°¡ Áõ°¡ÇÏ´Â °æÇâÀÌ ÀÖ¾ú´Ù( p=0.012). °á·Ð: Bcl-2 ´Ü¹é¹ßÇöÀÌ ¾ç¼ºÀÌ¸é ¾ÆÆ÷ÇÁÅä½Ã½º
Áö¼ö°¡
³·¾Ò°í, P53 ´Ü¹é¹ßÇöÀÌ ¾ç¼ºÀ̸é Ki-67 ¼¼Æ÷Áõ½ÄÁö¼ö´Â ³ô¾Ò´Ù. ¶ÇÇÑ Bcl-2 ¾ç¼ºÀΠȯÀÚ¿¡¼­´Â ¾ÆÆ÷ÇÁÅä½Ã½º Áö¼ö¿Í Ki-67 ¼¼Æ÷Áõ½ÄÁö¼ö»çÀÌÀÇ ¾ç¼º ¿¬°ü¼ºÀ» º¸¿´´Âµ¥ ÀÌ´Â ¾ÆÆ÷ÇÁÅä½Ã½º°¡ Á¾¾çÀÇ ¼ºÀå¿¡ À־ ¼¼Æ÷ÀÇ Áõ½Ä°ú º°µµ·Î ºÐ¸®ÇÏ¿© »ý°¢ÇÒ ¼ö ¾ø´Â
°ÍÀÓÀ»
½Ã»çÇØÁØ´Ù°í º»´Ù.

Purpose: Tumor growth in a given neoplasm is the net result of cell proliferation and cell loss, and apoptosis is the most significant component of continuous cell loss in most tumors. In this study, we examined non-Hodgkin's lymphoma
(NHL,
n=67)
immunohistochemically for the presence of Bcl-2 oncoprotein and P53 protein and compared apoptotic indices (AIs) and Ki-67 proliferative indices (percentages of Ki-67 positive cells). Materials and Methods: 67 patients with NHL were
evaluated : 3
low-grade and 64 intermediate-grade. The phenotype was determined in 65 cases : 47 (70%) were B cell type and 18 (27%) were T cell type. AIs and Ki-67 proliferative indices were determined immunohistochemically and the overexpression of P53 and
Bcl-2
protein were also evalutated. Results: The overexpressions of Bcl-2 protein and P53 protein were found in 40% (26/65) and 31% (20/ 65). The AI ranged from 0% to 15% (mean 2.16, median 1.2). Cellular Bcl-2, which counteracts apoptosis, was
significantly (p=0.005) associated with AIs. Ki-67 proliferative indices ranged from 1% to 91% (mean 55.4), and P53 was significantly (p=0.000) associated with Ki-67 proliferative indices. A positive correlation between AIs and Ki-67
proliferative
indices was revealed (p=0.012) in Bcl-2 positive patients. Conclusion: In NHL, we observed a correlation between AIs and Bcl-2 expression, between Ki-67 proliferative indices and P53 expression, and between AIs and Ki-67 proliferative
indices in
Bcl-2 positive patients. Our results suggest that cell apoptosis may be inseparable from cell proliferation during tumor growth.

Å°¿öµå

ºñÈ£ÁöŲ¸²ÇÁÁ¾; ¾ÆÆ÷ÇÁÅä½Ã½º Áö¼ö; Ki-67 ¼¼Æ÷Áõ½ÄÁö¼ö; Bcl-2; P53; Non-Hodgkin's lymphoma; Apoptotic index; Ki-67 proliferative index; Bcl-2; P53;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS